An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia

Hoffmann-La Roche108 enrolled

Overview

This observational study will evaluate the use in clinical practice and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in stage III-IV chronic kidney disease patients not on dialysis receiving Mircera for the treatment of chronic renal anemia. Eligible patients will be followed for 24 weeks.

Study Type

OBSERVATIONAL

Enrollment

108

Conditions

Anemia

Interventions

C.E.R.A.DRUG

Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, 18 to 65 years of age, inclusive * Patients with stage III-IV chronic kidney disease not on dialysis * Erythropoiesis stimulating agent (ESA) naïve with Hb \< 10 g/dL, or on treatment with ESAs other than Mircera and Hb within the target range of 10-12 g/dL * Adequate iron status as judged by the treating physician Exclusion Criteria: * Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication * Clinically significant concomitant disease or disorder as defined by protocol * Clinical suspicion of pure red cell aplasia (PRCA) * Planned elective surgery during the study period , except for cataract surgery or vascular access surgery * Transfusion of red blood cells in the previous 2 months * Pregnant women * Contraindications for Mircera according to local prescribing information or as judged by the investigator

Locations (6)

Unnamed facility

Bhubaneswar, India

Unnamed facility

Hyderabad, India

Unnamed facility

Mumbai, India

Unnamed facility

Mumbai, India

Unnamed facility

Vadodara, India

Outcomes

Primary Outcomes

Mean Height of Participants at Baseline (Week 0)

The mean body height of the participants was measured and summarized in centimeters (cm). Baseline is defined as Week 0.

Time frame: At Baseline (Week 0)

Mean Weight of Participants at Baseline (Week 0)

The mean body weight of the participants was measured and summarized in kg. Baseline is defined as Week 0.

Time frame: At Baseline (Week 0)

Number of Participants With Co-morbidities at Baseline (Week 0)

Co-morbidities were those medical disorders present in the medical history but unresolved at Baseline. The number of participants with different co-morbidities is presented. Baseline is defined as Week 0.

Time frame: At Baseline (Week 0)

Mean Time to Achieve Target Hemoglobin Range (10-12 Gram/Deciliter)

Correction of anemia was evaluated in participants with Hb \< 10 gram/deciliter (g/dL). Hemoglobin levels were recorded for each participant at enrollment and at different time points during the study up to Week 24. The mean time required to achieve target Hb range (10-12 g/dL) was calculated using the following formula: Time to achieve target range = (Date of Hb evaluation when participant achieves target range at first time - visit date of first dosing) + 1.

Time frame: Up to Week 24

Percentage of Participants Maintaining Hemoglobin Level Within 1 Gram/Deciliter of Baseline Value

Maintenance of Hb levels was to be evaluated for participants on Erythropoiesis stimulating agent (ESA) with Hb levels 10-12 g/dL. None of the participants in the enrolled population had received treatment with other ESAs and had pre-therapy Hb level as 10 g/dL or above. Therefore, the percentage of participants who had received treatment with other ESAs and were maintaining Hb level within 1 g/dL of baseline value during the study could not be evaluated. Baseline is defined as Week 0.

Time frame: Up to Week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Percentage of Participants Achieving Hemoglobin Target Range (10-12 Gram/Deciliter) at Least Once During the Study

Correction of anemia was evaluated in participants with Hb \< 10 g/dL at enrollment. Hemoglobin levels were recorded for each participant at enrollment and at different time points during the study up to Week 24. The percentage of participants achieving the target Hb range (10-12 g/dL) at least once during the study is presented.

Time frame: Up to Week 24

Mean Time Spent in the Hemoglobin Target Range (10 - 12 Gram/Deciliter)

The Hb concentration was recorded for all the participants at enrollment and different time points throughout the study up to Week 24. The mean time spent (in weeks) by the participants in the target range (10 - 12 g/dL) is presented.

Time frame: Up to Week 24

Mean Dose of C.E.R.A. Administered

The mean dose of C.E.R.A. administered during the study is reported. This accounts for the study drug injected through subcutaneous route at a frequency of every 4 weeks or once a month and every 2 weeks or fortnightly.

Time frame: Up to Week 24

Number of Doses of C.E.R.A. Administered by Different Routes

The number of doses of C.E.R.A. administered by the intravenous or subcutaneous route is presented. The number of doses for total population is calculated by summation and presented in table below as per routes of administration.

Time frame: Up to Week 24

Number of Participants Who Received Concomitant Treatment for Anemia

Medications that were used during the study treatment period (from the date of first dose of study medication to the end of the study) were included as concomitant medications. The number of participants taking concomitant medications prescribed for the treatment of anemia (for example iron) is presented.

Time frame: Up to Week 24

Number of Participants With Adverse Events and Serious Adverse Events

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during this study were reported as AEs. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

Time frame: Up to Week 24